Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiora Pharmaceuticals (KPRX) EBITDA Margin (2016 - 2024)

Kiora Pharmaceuticals (KPRX) has disclosed EBITDA Margin for 8 consecutive years, with 11015.04% as the latest value for Q2 2024.

  • For the quarter ending Q2 2024, EBITDA Margin changed N/A year-over-year to 11015.04%, compared with a TTM value of 60421.33% through Mar 2025, down 6043857.0%, and an annual FY2024 reading of 21.82%, changed N/A over the prior year.
  • EBITDA Margin was 11015.04% for Q2 2024 at Kiora Pharmaceuticals, down from 83.57% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 293029.45% in Q1 2021 and bottomed at 11015.04% in Q2 2024.
  • Average EBITDA Margin over 3 years is 91032.62%, with a median of 67572.21% recorded in 2021.
  • Peak annual rise in EBITDA Margin hit 15074545bps in 2021, while the deepest fall reached 15074545bps in 2021.
  • Year by year, EBITDA Margin stood at 10854.28% in 2020, then surged by 1389bps to 139891.17% in 2021, then plummeted by -108bps to 11015.04% in 2024.
  • Business Quant data shows EBITDA Margin for KPRX at 11015.04% in Q2 2024, 83.57% in Q1 2024, and 139891.17% in Q4 2021.